Navigation Links
U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
Date:1/29/2008

ts inception in 1998, MEDMARX has received more than 1.2 million reports of medication errors from more than 870 health care facilities across the U.S. MEDMARX is the largest nongovernmental, Internet- accessible database of medication errors in the U.S. USP also operates, in conjunction with the Institute for Safe Medication Practices, a Medication Errors Reporting Program (MER). Data from MER, which allows health care professionals to report potential and actual medication errors directly to USP on a confidential and anonymous basis, were also used in compiling the MEDMARX report. USP recently announced a strategic alliance with Quantros(TM), providers of hospital applications. Under this arrangement, the MEDMARX database will grow even larger and more robust with the addition of Quantros' extensive patient-safety events database.

USP-Advancing Public Health Since 1820

The United States Pharmacopeia (USP) is a private, non-profit, standards-setting organization that advances public health by ensuring the quality and consistency of medicines, promoting the safe and proper use of medications, and verifying ingredients in dietary supplements. These standards, which are recognized worldwide, are developed by a unique process of public involvement through the contributions of volunteers representing pharmacy, medicine, and other health care professions, as well as science, academia, government, the pharmaceutical industry, and consumer organizations. For more information about USP and its four public health programs, visit http://www.usp.org/newscenter.


'/>"/>
SOURCE U.S. Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. US Pharmacopeia partners with Quantros to enhance the MEDMARX patient safety reporting program
2. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
3. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
4. Pharmacopeia Announces Senior Additions to Management Team
5. Michigan Dentists Giving Free Dental Care to Low-Income Children During Annual Give Kids a Smile Program Starting February 1
6. Nanotech Briefs Announces Call for Nominations for the Fourth Annual Nano 50(TM) Awards
7. DrScore.com Releases Annual Report Card on Patient Satisfaction in the U.S.
8. Diabetes Health Toll Hits $174 Billion Annually
9. Weight Watchers to Present at Credit Suisse 10th Annual Global Services Conference
10. ATS Medical Participating in 44th Annual STS Annual Meeting
11. Ohio Dental Volunteers to Give Over $1.1M in Free Care and Improve Oral Health of 18,000 Children in Need Through 6th Annual Give Kids A Smile! Day Ohio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Dr. Redlener Applauds Historic Effort but Points out Potential Risk if America,s Safety Net Programs Are Lost in Final Health Care Reform ,, NEW YORK, Dec. 4 The New England Journal of Medicine
Breaking Medicine News(10 mins):Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2
...hool districts receiving grants to ...fourth consecutive year, Blue,Cross Blue Shield of... are,helping schools across the state launch activ...ssential activities to promote physical activity, ...
...university Karolinska Institutet have shown that h...val of the uterus greatly increases the risk of u...om a nationwide study, are presented in The Lancet...in order to improve life quality for the patients....
...to be a multi-stage, multi-mechanism process by an...the role of Helicobacter pylori (H pylori) in the ...rticle to be published on November 7 in the World ... structures necessary for cell differentiation, ti...
...cal,Systems, (NYSE: VAR ) has been ranked first i...he ServiceTrak(TM) 2007 survey report on radiation...esearch company that,analyzes service trends in va...out of 34 of the service attributes covered,by thi...
...lack Engineer and Information, Technology Magazin...ity, ABBOTT PARK, Ill., Oct. 26 Abbott (NYSE: A...for diversity in two publications.,Abbott was name...iversity in the magazine. In addition, Abbott was,...
...anization dedicated to autism spectrum diso...IEGO, Oct. 26 The San Diego County,Chapter of the...TACA and,the Autism Society of America, are offeri... "Offers of support for fire victims from both th...
Other Medicine News:Health News:Blue Cross Blue Shield of Michigan and Schools Partner to Get Kids More Active 2Health News:Blue Cross Blue Shield of Michigan and Schools Partner to Get Kids More Active 3Health News:Blue Cross Blue Shield of Michigan and Schools Partner to Get Kids More Active 4Health News:Blue Cross Blue Shield of Michigan and Schools Partner to Get Kids More Active 5Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2Health News:Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals 2Health News:Abbott Again Honored as a Leader in Diversity 2Health News:Abbott Again Honored as a Leader in Diversity 3Health News:ASA San Diego Offers Resources and Information to Families with Autism in Wake of Fires 2
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Scientists find that individuals in vegetative states can learn 9986 1Scientists find that individuals in vegetative states can learn 9986 2New Chemo Regimen May Benefit Ovarian Cancer Patients 57711 1New Chemo Regimen May Benefit Ovarian Cancer Patients 57711 2U of C alumnus finds high numbers of heat loving bacteria in cold Arctic Ocean 9984 1U of C alumnus finds high numbers of heat loving bacteria in cold Arctic Ocean 9984 2
... inhibitor, and R7128, nucleoside polymerase inhib...load in patients with hepatitis C - , , NUTLEY, ... 25 Roche, InterMune, Inc. (Nasdaq: ITMN ) and ...irst results from their innovative, interferon-fre...tion therapy for the treatment of patients chronic...
...ion milestone payment to Pharmasset , , PRINCETON... ) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHH...n dosed in a Phase IIb study of R7128, the nucleos...ent for the treatment of chronic hepatitis C (HCV)... treatment of R7128 in combination with Roche,s PE...
Other Medicine Technology:Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 2Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 3Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 4Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 5Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 6Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 7Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 8Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 9Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 10Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 11Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: